# Lazarus Response to Selpercatinib for Bleeding Colic Metastasis in a Patient With RET Fusion-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report

## TL;DR

A patient with a rare lung cancer achieved a strong response to selpercatinib, showing the drug's potential for treating RET fusion-positive pulmonary sarcomatoid carcinoma.

## Contribution

First reported case of selpercatinib effectiveness in RET fusion-positive pulmonary sarcomatoid carcinoma with a bleeding metastasis.

## Key findings

- Patient with RET fusion-positive PSC showed dramatic response to selpercatinib.
- Treatment led to significant clinico-radiological improvement despite poor initial condition.
- Selpercatinib may be a viable option for rare, aggressive lung cancer subtypes.

## Abstract

In recent years, the widespread use of next-generation sequencing (NGS) allowed clinicians to identify and treat non-small cell lung cancer (NSCLC) efficiently with target therapy. RET inhibitors, like selpercatinib and pralsetinib, for RET rearrangements in lung cancer showed high efficacy and clinical benefit. Nevertheless, to date, the use of molecular-targeted agents has not been tested in all lung cancer subtypes. Indeed, pulmonary sarcomatoid carcinoma (PSC) remains a rare form of NSCLC, unresponsive to standard chemotherapy, and associated with extremely poor prognosis.

We report the first case of a patient affected by RET fusion-positive PSC with a bleeding colic metastasis and a consequent poor performance status who achieved a dramatic response to selpercatinib and a remarkable clinico-radiological benefit.